Total submissions: 17
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genomic Research Center, |
RCV000001176 | SCV000784243 | pathogenic | Hereditary spastic paraplegia 11 | 2018-03-05 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000001176 | SCV000823844 | pathogenic | Hereditary spastic paraplegia 11 | 2024-11-05 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Glu1026Argfs*4) in the SPG11 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SPG11 are known to be pathogenic (PMID: 19105190, 20110243, 22154821, 26556829). This variant is present in population databases (rs312262752, gnomAD 0.01%). This premature translational stop signal has been observed in individuals with autosomal recessive juvenile amyotrophic lateral sclerosis, and hereditary spastic paraplegia (PMID: 18067136, 19105190, 19194956, 20110243, 27071356, 27084228, 28991695). It has also been observed to segregate with disease in related individuals. This variant is also known as c.3076insA, c.3076_3077insA, and c.3075_3076insA,. ClinVar contains an entry for this variant (Variation ID: 1117). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Paris Brain Institute, |
RCV000001176 | SCV001451255 | pathogenic | Hereditary spastic paraplegia 11 | criteria provided, single submitter | clinical testing | ||
Kariminejad - |
RCV001813929 | SCV001755384 | pathogenic | Abnormal central motor function | 2021-07-10 | criteria provided, single submitter | clinical testing | |
Institute for Clinical Genetics, |
RCV002247231 | SCV002010947 | pathogenic | not provided | 2021-11-03 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV002247231 | SCV002520053 | pathogenic | not provided | 2021-12-10 | criteria provided, single submitter | clinical testing | PM2, PM3, PS4_moderate, PVS1_strong |
Genome- |
RCV001762029 | SCV002764002 | pathogenic | Amyotrophic lateral sclerosis type 5 | criteria provided, single submitter | clinical testing | ||
Genome- |
RCV000001176 | SCV002764003 | pathogenic | Hereditary spastic paraplegia 11 | criteria provided, single submitter | clinical testing | ||
Broad Center for Mendelian Genomics, |
RCV000001176 | SCV003761347 | pathogenic | Hereditary spastic paraplegia 11 | 2023-01-25 | criteria provided, single submitter | curation | The homozygous p.Glu1026ArgfsTer4 variant in SPG11 was identified by our study in two siblings with spastic paraplegia. The p.Glu1026ArgfsTer4 variant in SPG11 has been previously reported in 17 unrelated individuals with hereditary spastic paraplegia 11 (PMID: 29983107, PMID: 35906604, PMID: 35348942, PMID: 32383541, PMID: 18067136, PMID: 19105190, PMID: 19194956, PMID: 20110243, PMID: 27071356, PMID: 27084228, PMID: 28991695) and segregated with disease in 7 affected members from 3 families (PMID: 35348942, PMID: 19194956, PMID: 20110243), but has been identified in 0.01% (3/21626) of European (Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs312262752). Although this variant has been seen in the general population in a heterozygous state, its frequency is low enough to be consistent with a recessive carrier frequency. Of these 17 unrelated affected individuals (PMID: 29983107, PMID: 35906604, PMID: 35348942, PMID: 32383541, PMID: 18067136, PMID: 19105190, PMID: 19194956, PMID: 20110243, PMID: 27071356, PMID: 27084228, PMID: 28991695), 8 were homozygotes (PMID: 19194956, PMID: 20110243, PMID: 32383541, PMID: 18067136) and 8 were compound heterozygotes who carried pathogenic or likely pathogenic variants in trans (PMID: 29983107, PMID: 35906604, PMID: 35348942, PMID: 32383541, PMID: 19105190, ClinVar ID: 41313; PMID: 27071356 , PMID: 27084228, PMID: 28991695), which increases the likelihood that the p.Glu1026ArgfsTer4 variant is pathogenic. This variant has also been reported in ClinVar (Variation ID: 1117) and has been interpreted as pathogenic by multiple submitters. This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 1026 and leads to a premature termination codon 4 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the SPG11 gene is an established disease mechanism in autosomal recessive SPG11-related neurologic disease. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive spastic paraplegia 11. ACMG/AMP Criteria applied: PVS1, PM2_Supporting, PM3_VeryStrong, PP1_Moderate (Richards 2015). |
Neurogenomics Lab, |
RCV000001176 | SCV003930340 | pathogenic | Hereditary spastic paraplegia 11 | 2024-05-22 | criteria provided, single submitter | research | PM2_supporting: the highest population allele frequency in gnomAD v4.0 is 0.0001095 (0.001%; 7/63948 alleles in European Finnish population) and in gnomAD v3.1.2 is 0.00002413 (0.002%; 1/ 41440 alleles in African/African American population) and the variant is absent from an internal database of 1074 control alleles. PP1_moderate: variant segregates with 2 informative meioses in 1 family. PM3_strong: 3 points awarded for 2 homozygous occurrences, 2 observations with pathogenic variant but phase unknown and 1 observation with pathogenic variant confirmed in trans. PVS1_met: null variant (nonsense or frameshift variant, predicted to undergo NMD, exon is present in biologically-relevant transcript) in a gene where LOF is a known mechanism of disease. Sequencing funded by the International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD): https://www.ucl.ac.uk/genomic-medicine-neuromuscular-diseases/. |
Gene |
RCV002247231 | SCV004022990 | pathogenic | not provided | 2023-01-24 | criteria provided, single submitter | clinical testing | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 28991695, 29983107, 32383541, 27071356, 35254204, 20110243, 18067136) |
Ce |
RCV002247231 | SCV004136525 | pathogenic | not provided | 2022-10-01 | criteria provided, single submitter | clinical testing | SPG11: PVS1, PM2, PM3, PS4:Moderate |
Clinical Genetics Laboratory, |
RCV002247231 | SCV005198341 | pathogenic | not provided | 2022-07-13 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005007806 | SCV005637903 | pathogenic | Amyotrophic lateral sclerosis type 5; Hereditary spastic paraplegia 11; Charcot-Marie-Tooth disease axonal type 2X | 2024-03-21 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000001176 | SCV000021326 | pathogenic | Hereditary spastic paraplegia 11 | 2009-10-05 | no assertion criteria provided | literature only | |
Gene |
RCV000001176 | SCV000058141 | not provided | Hereditary spastic paraplegia 11 | no assertion provided | literature only | ||
Prevention |
RCV004748491 | SCV005350127 | pathogenic | SPG11-related disorder | 2024-03-05 | no assertion criteria provided | clinical testing | The SPG11 c.3075dupA variant is predicted to result in a frameshift and premature protein termination (p.Glu1026Argfs*4). This variant has been reported in the homozygous or compound heterozygous state in individuals with hereditary spastic paraplegia (see for example, Balicza et al. 2016. PubMed ID: 27084228; Khani et al. 2020. PubMed ID: 32383541; Schneider-Gold et al. 2017. PubMed ID: 28991695). This variant is reported in 0.014% of alleles in individuals of European (Finnish) descent in gnomAD. Frameshift variants in SPG11 are expected to be pathogenic. This variant is interpreted as pathogenic. |